ISSN:

移植レポート : オープンアクセス

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Compared to the General Population, the Clinical Outcome of COVID19-Affected Solid Organ Transplant Recipients Underwent a Systematic Review and Meta-Analysis

Maddalena Giannella

Background: COVID-19 severity is about by cardio metabolic risk factors that can be further aggravated by chronic disorder in organ transplant recipients (ktrs). We've AN inclination to aimed to verify the foremost risk factors associated with high force per unit space (HTN) that contribute to COVID-19 progression and mortality in this population. Methods: Retrospective analysis of three hundred ktrs from March 2020 to August 2020 in a {very} very single center. We’ve AN inclination to compared the foremost outcomes between HTN (n = 225) and non-HTN (n = 75), what is more as admission to the treatment unit (ICU), development of acute organ injury (AKI), would like for invasive mechanical ventilation or O, and mortality. Results: Of the patients within the study, 57.3% were male, 61.3% were white, and therefore the mean age was fifty a pair of.5 years, and seventy fifth had HTN. Pre-existing HTN was severally related to higher rates of mortality (32.9%, OR = 1.96, p = 0.036), transfer to the unit (50.7%, OR = 1.94, p = 0.017), and AKI with chemical analysis (HD) demand (40.4%, OR = 2.15, p = 0.011). Within the hypertensive cluster, age, diabetes, upset, smoking, glycaemic management before admission, globulin, suckle dehydrogenase, lymphocytes, and D-dimer were considerably related to COVID-19 progression and mortality. Each lower basal and former calculable capillary filtration rates show ktrs with HTN at larger risk for HD demand. Conclusions: so, the first identification of things that predict COVID-19 progression and mortality in ktrs suffering from COVID-19 contributes to therapeutic decisions, patient flow management, and allocation of resources.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。